The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NO.sub.x gas directly to the organ(s).

An object of the present invention is to provide a means capable of stably storing an extracellular vesicle. The present invention relates to a storage stabilizer for an extracellular vesicle, which contains a copolymer containing a monomer unit derived from vinylpyrrolidone and a monomer unit derived from vinyl acetate, or a polymer having a monomer unit derived from vinylpyrrolidone such as polyvinylpyrrolidone and relates to a storage stabilization method for an extracellular vesicle, which includes cryopreserving an extracellular vesicle in the presence of the polymer.

The disclosure discloses an anti-lesion storage method and storage system for cells, tissues and organs, and relates to the technical field of storage of cells, tissues or organs. The method includes: adjusting a partial pressure of carbon dioxide in a suspension medium containing cells, tissues or organs to be stored to 30-50 mmHg. The inventors found that the regulation of the partial pressure of carbon dioxide in the suspension medium is advantageous for improving anti-lesions of cells, tissues or organs. In particular, the regulation of the partial pressure of carbon dioxide in the suspension medium can prolong the in vivo survival of platelets after transfusion of a platelet concentrate and protect the hemostatic function of platelets whiling effectively alleviating PSLs.

The disclosure discloses an anti-lesion storage method and storage system for cells, tissues and organs, and relates to the technical field of storage of cells, tissues or organs. The method includes: adjusting a partial pressure of carbon dioxide in a suspension medium containing cells, tissues or organs to be stored to 30-50 mmHg. The inventors found that the regulation of the partial pressure of carbon dioxide in the suspension medium is advantageous for improving anti-lesions of cells, tissues or organs. In particular, the regulation of the partial pressure of carbon dioxide in the suspension medium can prolong the in vivo survival of platelets after transfusion of a platelet concentrate and protect the hemostatic function of platelets whiling effectively alleviating PSLs.

Disclosed is an oxygenator device for oxygenating a perfusate solution to be perfused through an organ or tissue. The device includes an inlet configured to receive oxygen from an oxygen supply; and tubing connected to the inlet, the tubing including a plurality of holes by which the received oxygen may exit the tubing.

Disclosed is an oxygenator device for oxygenating a perfusate solution to be perfused through an organ or tissue. The device includes an inlet configured to receive oxygen from an oxygen supply; and tubing connected to the inlet, the tubing including a plurality of holes by which the received oxygen may exit the tubing.

The present inventive concept provides non-toxic compositions including ethanol, a polymer, and a polar aprotic solvent and methods of using the same in the field of preservation of plant, human and non-human animal tissue and anatomic pathology disciplines (e.g., surgical pathology, histopathology, cytopathology, forensic pathology). In particular, the compositions provide a safer alternative to aldehyde-based compositions.

The present inventive concept provides non-toxic compositions including ethanol, a polymer, and a polar aprotic solvent and methods of using the same in the field of preservation of plant, human and non-human animal tissue and anatomic pathology disciplines (e.g., surgical pathology, histopathology, cytopathology, forensic pathology). In particular, the compositions provide a safer alternative to aldehyde-based compositions.

The present disclosure provides methods and compositions for reducing or preventing loss of keratocytes, keratinocytes, and/or keratoblasts, restoring keratocytes, keratinocytes, and/or keratoblasts, inhibiting apoptosis to prevent loss of cells in the eye or skin caused by surgical procedure, injury, or disease, preventing or minimizing refractive regression and subepithelial scarring, treating corneal wounds, treating dermal or ophthalmic diseases, disorders and/or conditions, or storing a biological sample.

The present disclosure provides methods and compositions for reducing or preventing loss of keratocytes, keratinocytes, and/or keratoblasts, restoring keratocytes, keratinocytes, and/or keratoblasts, inhibiting apoptosis to prevent loss of cells in the eye or skin caused by surgical procedure, injury, or disease, preventing or minimizing refractive regression and subepithelial scarring, treating corneal wounds, treating dermal or ophthalmic diseases, disorders and/or conditions, or storing a biological sample.